Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of medicinal therapies intended to improve quality of life and resolve serious unmet medical needs, self-described.

Summit Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need.

Applied Therapeutics

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc.

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Metric
Company Name	Summit Therapeutics	Applied Therapeutics	Ardelyx, Inc.	Avidity Biosciences, Inc.
Symbol			ARDX	RNA
MSH ID	COM:SUMMITTHERAPEUTICS	COM:APPLIEDTHERAPEUTICS	COM:ARDELYX	COM:AVIDITYBIOSCIENCES
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US	US
Stage	Post-IPO Equity		Debt
Employee Count			267	253
Website	summittherapeutics.com	appliedtherapeutics.com	ardelyx.com	aviditybiosciences.com
LinkedIn
Founders

Metric
Market Cap		1.30B	4.07B
Enterprise Value
Monthly Web Traffic	1.36K	33.50K
Web Traffic Growth	-0.08	2.80
Valuation
Raised Capital	235M	20M

Metric
Revenue	124.46M	9.56M
Revenue (LTM)
Revenue (NTM)
Gross Profit	106.66M	7.46M
EBITDA	-55.35M	-233.50M
Operating Income	-63.28M	-235.60M
Net Income	-66.07M	-212.22M
EPS	-0.30	-2.91
Diluted EPS	-0.30	-2.91
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.86	0.76
Operating Profit Margin	-0.28	-23.48
EBITDA Margin	-0.44	-24.42
Net Profit Margin	-0.31	-21.04
Return on Equity	-0.40	-0.33
Return on Assets	-0.19	-0.19
Return on Capital Employed	-0.21	-0.23

SUMM

COM:SUMMITTHERAPEUTICS

Summit Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-74.58	-4.46
P/B Ratio	10.37	1.68
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	14.47	557.48
EV Multiple	-20.25	-8.85

Metric
Days Sales Outstanding	117.61
Days Payables Outstanding	185.33
Days Inventory Outstanding	264.91
Operating Cycle	329.52	72.73
Cash Conversion Cycle	100.07
Asset Turnover	0.61	0.02

Metric
Operating Cash Flow	-89.72M	-119.06M
Free Cash Flow	-90.06M	-123.29M
Cash Flow to Debt	-0.77	-12.09
Operating Cash Flow/Sales	-0.41	-12.45
Free Cash Flow Yield	-0.03	-0.21

Metric
Cash & Equivalents	21.47M	185.08M
Accounts Receivable	-14.30M
Inventory	12.45M
Goodwill
Debt to Capitalization	0.41	0.02
Debt to Assets	0.12	0.02
Current Ratio	5.54	11.40
Quick Ratio	4.36	15.97

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.09	3.52
R&D to Revenue	0.26	18.13
SG&A to Revenue	0.15	4.78